npy sirna Search Results


npy sirna  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology npy sirna
FIGURE 3 Upregulation of neuropeptide Y <t>(NPY)</t> expression in the left stellate ganglion (SG) and cardiac sympathetic nerves. (A) mRNA expression of various neuronal markers in the left SG in the control (CTL) and stress cardiomyopathy (SC) groups. SGs in SC model were collected 2 h after the commencement of epilepsy. NPY expression was significantly increased in the SC model, whereas there was no increase in the expression of the choline transporter (CHT), choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAchT), or tyrosine hydroxylase (TH; n = 5). (B,C) Triple-immunohistochemistry staining of the left SG and left ventricle (LV) for TH (green), NPY (red), and 4′,6′-diamidino-2-phenylindole (DAPI; nuclei; blue). NPY upregulation was observed in the SG and cardiac sympathetic nerve of the LV in the SC model. Scale bars: 50 µm (B) and 100 µm (C). (D) NPY content of the apical part of the LV in control and SC rats (n = 6). (E) Expression level of NPY mRNA significantly reduced following the injection of NPY <t>siRNA</t> into left SG compared to control siRNA (n = 6). Where appropriate, data are provided as the mean ± SD. *P < 0.05 relative to the control.
Npy Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/npy sirna/product/Santa Cruz Biotechnology
Average 91 stars, based on 1 article reviews
npy sirna - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
npy sirnas  (GenScript corporation)
90
GenScript corporation npy sirnas
FIGURE 3 Upregulation of neuropeptide Y <t>(NPY)</t> expression in the left stellate ganglion (SG) and cardiac sympathetic nerves. (A) mRNA expression of various neuronal markers in the left SG in the control (CTL) and stress cardiomyopathy (SC) groups. SGs in SC model were collected 2 h after the commencement of epilepsy. NPY expression was significantly increased in the SC model, whereas there was no increase in the expression of the choline transporter (CHT), choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAchT), or tyrosine hydroxylase (TH; n = 5). (B,C) Triple-immunohistochemistry staining of the left SG and left ventricle (LV) for TH (green), NPY (red), and 4′,6′-diamidino-2-phenylindole (DAPI; nuclei; blue). NPY upregulation was observed in the SG and cardiac sympathetic nerve of the LV in the SC model. Scale bars: 50 µm (B) and 100 µm (C). (D) NPY content of the apical part of the LV in control and SC rats (n = 6). (E) Expression level of NPY mRNA significantly reduced following the injection of NPY <t>siRNA</t> into left SG compared to control siRNA (n = 6). Where appropriate, data are provided as the mean ± SD. *P < 0.05 relative to the control.
Npy Sirnas, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/npy sirnas/product/GenScript corporation
Average 90 stars, based on 1 article reviews
npy sirnas - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
synthetic lnacontaining sirna: npy luc  (Santaris Pharma A/S)
90
Santaris Pharma A/S synthetic lnacontaining sirna: npy luc
FIGURE 3 Upregulation of neuropeptide Y <t>(NPY)</t> expression in the left stellate ganglion (SG) and cardiac sympathetic nerves. (A) mRNA expression of various neuronal markers in the left SG in the control (CTL) and stress cardiomyopathy (SC) groups. SGs in SC model were collected 2 h after the commencement of epilepsy. NPY expression was significantly increased in the SC model, whereas there was no increase in the expression of the choline transporter (CHT), choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAchT), or tyrosine hydroxylase (TH; n = 5). (B,C) Triple-immunohistochemistry staining of the left SG and left ventricle (LV) for TH (green), NPY (red), and 4′,6′-diamidino-2-phenylindole (DAPI; nuclei; blue). NPY upregulation was observed in the SG and cardiac sympathetic nerve of the LV in the SC model. Scale bars: 50 µm (B) and 100 µm (C). (D) NPY content of the apical part of the LV in control and SC rats (n = 6). (E) Expression level of NPY mRNA significantly reduced following the injection of NPY <t>siRNA</t> into left SG compared to control siRNA (n = 6). Where appropriate, data are provided as the mean ± SD. *P < 0.05 relative to the control.
Synthetic Lnacontaining Sirna: Npy Luc, supplied by Santaris Pharma A/S, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/synthetic lnacontaining sirna: npy luc/product/Santaris Pharma A/S
Average 90 stars, based on 1 article reviews
synthetic lnacontaining sirna: npy luc - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


FIGURE 3 Upregulation of neuropeptide Y (NPY) expression in the left stellate ganglion (SG) and cardiac sympathetic nerves. (A) mRNA expression of various neuronal markers in the left SG in the control (CTL) and stress cardiomyopathy (SC) groups. SGs in SC model were collected 2 h after the commencement of epilepsy. NPY expression was significantly increased in the SC model, whereas there was no increase in the expression of the choline transporter (CHT), choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAchT), or tyrosine hydroxylase (TH; n = 5). (B,C) Triple-immunohistochemistry staining of the left SG and left ventricle (LV) for TH (green), NPY (red), and 4′,6′-diamidino-2-phenylindole (DAPI; nuclei; blue). NPY upregulation was observed in the SG and cardiac sympathetic nerve of the LV in the SC model. Scale bars: 50 µm (B) and 100 µm (C). (D) NPY content of the apical part of the LV in control and SC rats (n = 6). (E) Expression level of NPY mRNA significantly reduced following the injection of NPY siRNA into left SG compared to control siRNA (n = 6). Where appropriate, data are provided as the mean ± SD. *P < 0.05 relative to the control.

Journal: Frontiers in neuroscience

Article Title: Upregulation of neuropeptide Y in cardiac sympathetic nerves induces stress (Takotsubo) cardiomyopathy.

doi: 10.3389/fnins.2022.1013712

Figure Lengend Snippet: FIGURE 3 Upregulation of neuropeptide Y (NPY) expression in the left stellate ganglion (SG) and cardiac sympathetic nerves. (A) mRNA expression of various neuronal markers in the left SG in the control (CTL) and stress cardiomyopathy (SC) groups. SGs in SC model were collected 2 h after the commencement of epilepsy. NPY expression was significantly increased in the SC model, whereas there was no increase in the expression of the choline transporter (CHT), choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAchT), or tyrosine hydroxylase (TH; n = 5). (B,C) Triple-immunohistochemistry staining of the left SG and left ventricle (LV) for TH (green), NPY (red), and 4′,6′-diamidino-2-phenylindole (DAPI; nuclei; blue). NPY upregulation was observed in the SG and cardiac sympathetic nerve of the LV in the SC model. Scale bars: 50 µm (B) and 100 µm (C). (D) NPY content of the apical part of the LV in control and SC rats (n = 6). (E) Expression level of NPY mRNA significantly reduced following the injection of NPY siRNA into left SG compared to control siRNA (n = 6). Where appropriate, data are provided as the mean ± SD. *P < 0.05 relative to the control.

Article Snippet: Thereafter (mechanically ventilated), their left stellate ganglia (SG) were microinjected with NPY siRNA (100 ng/0.5 μl; Santa Cruz Biochemical, Santa Cruz, CA, USA) using a Hamilton micropipette.

Techniques: Expressing, Control, Immunohistochemistry, Staining, Injection